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Abstract
Purpose: To validate the treatment-specific Treatment Satisfaction Survey for Intraocular Pressure (TSS-
IOP).
Methods: Item content was developed by 4 heterogeneous patient focus groups (n = 32). Instrument
validation involved 250 patients on ocular hypotensive medications recruited from ophthalmology
practices in the Southern USA. Participants responded to demographic and test questions during a clinic
visit. Standard psychometric analyses were performed on the resulting data.
Sample: Of the 412 patients screened, 253 consented to participate, and 250 provided complete datasets.
The sample included 44% male (n = 109), 44% Black (n = 109) and 57% brown eyed (n = 142) participants,
with a mean age of 64.6 years (SD 13.1) and a history of elevated IOP for an average of 8.4 yrs (SD 7.8).
A majority was receiving monotherapy (60%, n = 151).
Results: A PC Factor analysis (w/ varimax rotation) of the 31 items yielded 5 factors (Eigenvalues > 1.0)
explaining 70% of the total variance. Weaker and conceptually redundant items were removed and the
remaining 15 items reanalyzed. The satisfaction factors were; Eye Irritation (EI; 4 items), Convenience of
Use (CofU; 3 items), Ease of Use (EofU; 3 items), Hyperemia (HYP; 3 items), and Medication Effectiveness
(EFF; 2 items). Chronbach's Alphas ranged from .80 to .86. Greater distributional skew was found for less
common experiences (i.e., HYP & EI with 65% & 48.4% ceilings) than for more common experiences (i.e.,
EofU, CofU, EFF with 10.8%, 20.8% & 15.9% ceilings). TSS-IOP scales converged with conceptually related
scales on a previously validated measure of treatment satisfaction, the TSQM (r = .36 to .77). Evidence of
concurrent criterion-related validity was found. Patients' symptomatic ratings of eye irritation, hyperemia
and difficulties using the medication correlated with satisfaction on these dimensions (r = .30-.56, all p <
.001). Clinicians' ratings of IOP control, severity of side effects and problematic medication use correlated
with patients' satisfaction scores on these dimensions (r = .13-.26, all p < .01).
Conclusions: This study provides initial evidence that the TSS-IOP is a reliable and valid measure,
assessing patients' satisfaction with ocular hypotensive medications.
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Background
Introduction
Around the world, Patient Reported Outcomes (PRO's)
are becoming an increasingly important set of criteria with
which to evaluate the adequacy of treatment outcomes
[1–6]. The relative success or failure of medical treatments
can, at least in part, be judged by inquiring about patients'
perceptions of their treatment experiences and changes in
the impact of illness on their daily lives. . PRO self-report
assessments have been developed to assess patients' per-
ceptions of the type and severity of symptoms, the func-
tional impact of illness, utility and preference measures
for treatment options, the impact of illness on health-
related quality of life and well-being, and various types of
patient/treatment satisfaction.
More specifically, patient satisfaction has been used as a
way to include patients' perceptions and preferences when
evaluating the success of both medical treatments and sys-
tems of healthcare delivery [7–10]. Moreover, an individ-
uals' satisfaction has been shown to affect health-related
decisions and treatment-related behaviors, which in turn
impact the success of treatment outcomes and the costs
associated with treatment failure [11,12]. Patients' satis-
faction with services has been shown to predict treatment
success, medical compliance, follow-through with treat-
ment plans, and appropriate use of services [13–15]. In a
similar way, satisfaction with medication predicts patients
continuance on pharmaceutical treatment, correct medi-
cation use and compliance with medication regimens
[16–19].
The adverse effect of low treatment satisfaction on medi-
cation compliance has been found to be particularly prob-
lematic among persons with chronic disease conditions
[14,20]. It has been estimated that up to one half of
patients with chronic and/or asymptomatic illness will
make medication-related decisions without seeking med-
ical advice, becoming 'non-adherent' to such an extent
that they compromise the effectiveness of treatment and
eventually place further utilization demand on broader
systems of care [20]. In contrast, more acutely ill patients
who perceive an immediate threat to their physical well-
being may be more willing to tolerate short-term aggres-
sive treatment regimens in hopes of restoring their former
health. Primary open angle glaucoma is a disease where
patient adherence to therapy is important since the dis-
ease is by and large chronic, asymptomatic and can lead
to irreversible vision loss. Patient compliance with ther-
apy is necessary for optimal long-term outcomes. The
objective of this research is to validate a treatment-specific
Treatment Satisfaction Survey for Intraocular Pressure
(TSS-IOP).
Measurement Issues
Due to the central importance of consumer satisfaction to
the success of both health care services and pharmaceuti-
cal products, conceptual advances in the field have lead to
a proliferation of satisfaction measures across many dis-
ease states [21,22]. These measures can be grouped into
those addressing patients' satisfaction with discrete
aspects of medical treatments (treatment satisfaction) and
those focusing on more systemic aspects of programmatic
care [15,23–27]. As discussed in two articles describing
the development of a general model of treatment satisfac-
tion, patients' satisfaction with their medication (TS-M)
can be thought of as a specific sub-dimension of treatment
satisfaction (TS) [28,29]. In turn, TS is viewed as a subset
of patient satisfaction (PS) that covers more general and
systemic aspects of both medical treatments and interper-
sonal aspects of clinical care. Thus one may inquire about
patients' satisfaction across different aspects of both inter-
personal care and medical treatments or more specifically
about satisfaction with medication.
Adding to the complexity of this hierarchical model of PS,
TS, and TS-M, each class of instrumentation can be opera-
tionalized using measures that differ on a context-specific
to context-general continuum. Borrowing from concep-
tual work in the field of Quality of Life [14], items and
scales of TS-M measures can be thought of as existing on
one of three levels of generality-specificity (see Table 1).
Level 3 scales contain items that refer specifically to a par-
ticular set of circumstances and events related to a partic-
ular type of treatment or disease state (e.g., How satisfied
or dissatisfied are you with the way in which medication
X has relieved symptom Y associated with condition Z?).
Such items and scales do not rely heavily on respondents'
interpretation of an items' meaning due to the situational
specificity of the content, thus both respondents and scale
assessors can be fairly certain of what is being rated.
Table 1: Levels of Generality-Specificity of PRO Items and Scales
Levels of PRO Item and Scale 
Specificity
Content Specificity & 
Referential Certainty
Respondents' Inference or 
Interpretation of Meaning
Normative Index of Personal 
Relevance
Global: Level 1 None High High
General: Level 2 Domain Specific Only Moderate Moderate
Specific: Level 3 Domain & Event Specific Low LowHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/67
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Level 2 scales are made up of more general items that
assess a particular domain of treatment (e.g., effectiveness,
side effects or convenience) but are not specific to a cer-
tain illness or type of medication. In response to Level 2
items, respondents interpret the meaning of the item from
the vantage point of their particular experiences of treat-
ment (e.g., How satisfied or dissatisfied are you with how
well your medication has relieved the symptoms
associated with your condition?). As a result, such items
are appropriate for use with a wider range of patients with
different illness and treatment conditions. The quality of
these items depends heavily on the face validity of the per-
ceived relevance of the content. The items are interpreted
in such a way that they are understood to be personally
relevant, and the resulting response is reflective of a sali-
ent aspect of ones' experiences. The wording of Level 2
items refers generally to the dimension being evaluated
(e.g., Effectiveness, Side Effect, Convenience), not the par-
ticular disease-specific treatment experiences within each
dimension.
Level 1 scales are the most general or global of all. In addi-
tion to being seen as relevant across many different types
of patient populations, illness conditions, and treatment
approaches within a domain of satisfaction, Level 1 items
and scales elicit a global appraisal or judgment across
numerous domains of measure (e.g., Taking all things
into account, how satisfied or dissatisfied are you with
your medication overall?). As one moves from Level 3 to
Level 1, greater personal interpretation and judgment is
implicitly required from respondents. They make contex-
tual sense out of the more generally worded items using
sets of personally relevant experiences which stand out in
their mind. Moreover, these experiences have emotional
relevance, which may explain the stronger correlations
between emotional variables and Level 1 scales than Level
3 scales. In general, responses to more global scales have
been shown to exhibit higher correlations with affective
constructs than more specifically worded items [30]. An
exception to this observation may occur if a specific item
is relevant to the majority of a sample. It remains to be
seen whether such emotive associations and general
appraisals of satisfaction can be shown to predict behav-
ioral variables as they have in other populations [31].
Conversely, the content specificity of Level 2 and particu-
larly Level 3 items and scales is higher, and it is often easy
from reading these items to be fairly certain of what
respondents' are referring to when making ratings. As a
result, Level 3 items are often viewed more favorably pro-
viding evidence to substantiate specific claims regarding
particular treatment or aspects of care [32].
PRO Measurement in Glaucoma
The importance of patients' perceptions of both clinical
and non-clinical factors affecting the outcomes of oph-
thalmology has lead to the development of various PRO
measures for use with glaucoma patients. PRO instru-
ments have been used to assess patients' perceptions of
visual functioning [33–35], visual disabilities [36], visual
symptoms [37], patient preference and treatment satisfac-
tion [38], and Health-Related Quality of Life [39]. As one
might expect, an inter-relationship has been shown
between various types of PRO outcomes. For example, in
addition to patients' reports of their visual function [40],
TS-M (particularly the side effects domain) has been
shown to affect patients' health-related quality of life
scores [41].
Patient satisfaction measures have been used to assess
glaucoma patients' experiences with surgical procedures
[38,42], pharmaceutical interventions [43], and various
aspects of service delivery [44]. To date, only one valid
measure of TS-M for ocular hypotensive treatments exists,
the Comparison of Ophthalmic Medication for Tolerabil-
ity Questionnaire (COMTOL) [45]. However, this earlier
questionnaire places a heavy emphasis on vision-related
functional outcomes and does not adequately cover the
side effects that became apparent with the emergence of
prostaglandin treatments in 1996.
Glaucoma Treatments and Patient Experience
The reduction of intraocular pressure (IOP) in patients
with glaucoma helps prevent the progression of the dis-
ease which may lead to visual loss and potential blind-
ness. In addition, reduction in IOP is used to help prevent
the progression of OH to glaucoma [46,47]. Unfortu-
nately, the topical treatments for OH are often accompa-
nied by significant side effects [48,49]. Similar to
observations in other areas of medicine, the factors of
cost, convenience and side effects of pharmacotherapies
can influence a patient's lifestyle, quality of life, non-com-
pliance with medication regimens, and ultimately, their
clinical effectiveness [11–13,48,49].
In addition, multiple medications and multiple daily
administrations may be a necessary inconvenience and,
for a subset of patients with dexterity problems, present
significant difficulties to its use. Easy to use delivery sys-
tems that permit accurate dosing of topical agents are
important to minimize the wastage associated with miss-
ing the eye or instillation of multiple doses. The costs and
inconveniences associated with such waste are a substan-
tial concern for some patients.
Several clinical classes of medications are available to treat
elevated IOP in patients with POAG and OH. A frequently
administered class of medications is the prostaglandinHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/67
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analogs. These medications have the advantage of once
daily dosing, are highly efficacious and have a low inci-
dence of systemic side effects. The most common ocular
side effects are conjunctival hyperemia and iris pigmenta-
tion changes [50–52]. Another commonly prescribed
class of medicine is the topical beta-adrenergic blockers.
These medicines are generally slightly less effective than
prostaglandins and are dosed once or twice daily. The
beta-adrenergic blockers may be associated with pro-
nounced systemic side effects in some patients, including
worsening of reactive airway disease and aggravation of
cardiac conduction disease [46,53,54].
Topical carbonic anhydrase inhibitors (CAI) are available
as monotherapies or as a fixed combination with timolol
maleate, a beta-blocker, and may be dosed two to three
times daily. The CAI medicines, although less effective
than beta-blockers, provide an excellent systemic safety
profile but are commonly associated with mild ocular
burning and stinging upon instillation [55–57]. Brimoni-
dine is a centrally acting alpha-agonist that is usually
dosed two to three times daily and has similar efficacy to
dorzolamide. Brimonidine may occasionally cause sys-
temic side effects, such as blood pressure changes or neu-
rological symptoms and may cause ocular intolerance in
approximately 10%-26% of cases [57,58]. All the above
agents are often dosed as un-fixed combinations that
increase dosing complexity and the likelihood of adverse
events.
Unfortunately, no existing measure of treatment satisfac-
tion adequately assesses the subjective impact of ocular
side effects and inconveniences associated with different
IOP medications. In order to address this gap, the objec-
tive of this study was to design a measure of TS-M specifi-
cally to assess patients' satisfaction with various aspects of
topical ophthalmic treatments within a sample of patients
with glaucoma or ocular hypertension – the Treatment
Satisfaction Questionnaire for Medications for Intraocular
Pressure (TSS-IOP).
Study methods
This study occurred in two stages. The first portion was
conducted to identify the item content for the new meas-
ure, based on information gleaned from a literature
review and four focus groups consisting of patients receiv-
ing topical ophthalmic treatment to control IOP. This
content was used to develop an initial pool of items that
would be psychometrically tested in the second stage of
the study. This second, larger psychometric study was
used to select the final items to be included in the TSS-IOP
and to examine the performance of the new scales.
Stage I: Patient Focus Groups Qualitative Research 
Methodology
The primary objective of the focus groups was to refine
and finalize the content pool for the TSS-IOP test items.
The methodological approach used to plan and conduct
the patient focus groups was consistent with Goldman's
group depth interview model [59], in which information
is gathered from a number of interacting individuals who
share a community of interests. These groups are facili-
tated using a trained moderator who employs a combina-
tion of probing as well as direct- and non-direct inquiry
techniques.
Prior to implementing the focus groups, a discussion
guide was developed to direct the collection of data. The
guide consisted of nine sections: (1) orient participants to
the purpose of the discussion, (2) guide patient introduc-
tions, (3) discuss satisfaction with ocular hypotensive
medications, (4) identify determinants of medication sat-
isfaction and dissatisfaction, (5) explore three targeted
satisfaction domains (effectiveness, side effects, and con-
venience/ease-of-use/delivery method), (6) discuss com-
pliance, (7) inquire about doctor visits and the
continuum of care, (8) review a prototype TSS-IOP
mockup, and (9) probe for final thoughts, including
what, if any, additional domains could be added that
might impact satisfaction/dissatisfaction. The focus group
data were collected using the moderator's notes, notes
taken by two observers seated behind the one-way mirror
in the focus group facility, and via review of the session
videotapes.
Focus Group Composition
Thirty-two patients with primary open-angle glaucoma
(POAG) or ocular hypertension (OH) participated in one
of four, 90-minute focus group sessions. These sessions
were composed of a heterogeneous sample that repre-
sented a diversity of patient experiences with common
ocular hypotensive medications used to treat OH and
POAG. Focus group participants included: Those experi-
encing hyperemia associated with ophthalmic prostaglan-
din medications (PG) within the last 3–6 months;
patients who were newly treated in the past 3–6 months;
PG naive patients who received some form of topical ther-
apy other than PG's; patients who had used medications
that required multiple daily dosing (e.g., timolol,
brimonidine) or used multiple types of ophthalmic med-
ications daily; and patients using novel forms of medica-
tion delivery aids.
Twelve individuals reported problems with medication
effectiveness and seven admitted that they did not always
use their medication as prescribed. Fourteen participants
reported specific problems with the side effects of their
current medication, while 16 of patients reported havingHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/67
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experienced at least one ocular side effect associated with
their medication over time. Eight individuals were on two
or more medications at the time and of these, two
reported problems specifically associated with multiple
medication use (primarily side effects). Ten participants
indicated having at least some minor problems with
respect to the medication they have used in the past.
Thematic Content of Focus Group Discussion
Information gathered within the four focus group sessions
was tabulated by thematic content (see Table 2). These
themes were used to develop thirty-one items for
psychometric testing in the second stage of this study.
Stage II: Validation Study
Study Methods
Participants in the validation study consisted of 250
patients who were consecutively recruited from participat-
ing Ophthalmology clinics in 5 different clinics in the
Southeastern U.S. These patients had either open-angle
glaucoma or ocular hypertension and were currently using
marketed topical IOP-lowering medication(s) in at least
one eye (as defined by AAO diagnostic codes). In order for
patients to be included they were also required to meet the
following inclusion-exclusion criteria: Be 18 years of age
or older; willing to comply with the investigator's and pro-
tocol's instructions; consent to participate; be treated with
a topical ophthalmic hypotensive drop medication in at
least one eye; and possess adequate visual acuity and men-
tal ability to read and understand English. Individuals
were excluded if they had any clinically significant medi-
cal/psychiatric condition or had participated in any inves-
tigational ophthalmic trials within the previous 30 days.
Patients who had ocular surgery within the last 60 days
were also excluded.
Consenting participants were asked to complete the 31
draft treatment satisfaction items as well as a supplemen-
tal questionnaire gathering demographic and treatment-
related information. A study staff member reviewed the
materials for completeness prior to the end of their visit.
Participants' physicians also provided clinical informa-
tion about the level of side effects, degree of OH control,
and difficulties their patients had with compliance and
self-administration of their medication. In addition,
patients' current treatment information from their medi-
cal records was merged with their records in the study
dataset. This provided information on the types of topical
medications to treat OH. As a follow-up, twenty-five
patients were asked to complete the TSS-IOP and supple-
mental questionnaire twice, with assessments taken one
Table 2: Thematic Content Analysis of Factors Relevant to Patients' Satisfaction With Their Medication Use
Content Area Prevailing Themes and Sub-Themes
Medication Effectiveness • The eye pressure readings are the only way one can tell
• Some report improvements in their vision, including:
Ability to read (small print) without glasses
Vision is clearer/not as blurred or cloudy
Distance vision is clearer
Able to see better at night
Unintended Medication Effects • Burning, Itching, Grittiness/Sandiness, Dryness, Tearing of eyes
• Redness of eye, Darkening of iris of eyes
• Swelling, Crustiness, Stickiness of eyelids
• Visual Changes (e.g., "clear ropes" in eyes, loss of center of vision, sensitivity to light)
• Systemic affects associated with allergenic reaction or use of oral treatments: shortness of breath, 
restlessness/inability to sleep, excessive perspiration, low energy, migraines
Convenience and Ease of Medication Use • Discomfort putting things in eyes
• Strong "blink reflex" making it difficult to instill the drops
• Difficulty learning to instill drops
• Miss the eye when administering the medicine
• Unable to feel whether a drop has gone into their eye
• Inadvertently dispense more than one drop, or dispense just one more to be sure
• Require assistance if elderly or physically impaired (e.g., have Parkinson's)
• Trouble remembering to use the medicine, particularly on trips or vacations
• Instillation twice a day, this is less convenient than once
• Frustration with the daily dosing and, as a result, sometimes not taking their medicine
• More inconvenient to administer evening than morning doses, sometimes too tired in evening
• Delay taking medication in evening till returning home
• Difficult to tell when their medicine is about to run outHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/67
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week apart. The resulting information allowed for evalua-
tion of the test-retest reliability of the measure.
Statistical Methods
The sample size required for the study was based on the
requirements of the factor analytic procedure, which (as a
rule of thumb) requires 10 subjects per question [60]. All
statistical procedures and methods that were used in this
study followed the generally accepted guidelines for the
psychometric validation of PRO instrumentation [61–
63]. This included the examination of construct validity
using factor analysis and internal consistency of resulting
scales assessed using Chronbach's Alpha coefficients.
Computed scale scores allowed for assessment of the clin-
ical-criterion and convergent validity of the instrument.
The clinical criterion-related validity coefficients were
based on known differences in patient's clinical condition
and treatment experiences. The convergent validity of the
instrument was assessed using a previously validated
measure of treatment satisfaction, the Treatment Satisfac-
tion Questionnaire for Medication (TSQM) [29]. Inter-
class correlations were used to assess the temporal
stability of the scales under no change conditions.
Results
Sample Characteristics
Of the 412 patients approached, 252 patients consented,
and 250 provided complete datasets. The majority of
those who declined participation cited time constraints as
the major reason (n = 91), some (n = 39) were unable to
complete the survey without assistance due to current iris
dilation procedures, and some declined because they
thought the information was too personal (n = 32). Par-
ticipants had a mean age of 64.6 years (SD 13.1) and a his-
tory of elevated IOP for an average of 8.4 yrs (SD 7.8). The
sex ratio was about equal, with females representing
56.4% (141) of the sample. A slim majority of the sample
was Caucasian (138, 55.2%) with 109 (43.6%) being
Black and 3 (1.2%) Hispanic. The iris color of the sample
was predominantly brown (142, 56.8%), followed by
blue (67, 26.8%), and other light colors (41, 16.4%).
Fifty-four percent of the sample (n = 134) were retired,
39.6% were working either full- or part-time and 6.8%
were unemployed. A majority were receiving topical mon-
otherapy for OH (60.4%, n = 151). Almost 80% (197)
reported to have taken systemic forms of medication to
treat other comorbid conditions in addition to their eye
drops within the last 30 days.
Construct Validity & Scale Score Distributions
A principal components factor analysis (w/ varimax rota-
tion) yielded 5 factors (Eigenvalues > 1.0) explaining 70%
of the total variance. Weak or ambiguous items were
removed and the remaining 15 items reanalyzed. The
final factor analysis converged in six iterations and the five
factors, Eye Irritation (EI), Convenience of Use (CofU),
Ease of Use (EofU), Hyperemia (HYP) and Effectiveness
(EFF), explained 71.9% of the total pooled variance (see
Table 3).
Table 3: Final Five Factor Solution of the TSS-IOP Items
TSS-IOP Items Factors*
I II III IV V
EI_1: Bothered by prolonged burning or stinging .784 .204
EI_2: Bothered by grittiness or sandiness in eyes .778
EI_3: Bothered by dry eyes .765
EI_4: Bothered by unpleasant feelings in/around eyes .744 .268
CoU_1: Satisfaction w/ time of day to take medication .898 .217
CoU_2: Satisfaction w/ times per day require to take med .855 .206
CoU_3: Ease of remembering to take medication .764 .270
EoU_1: Ability to accurately deliver drop in eye .881
EoU_2: Ability to deliver the right amount of medication .233 .858
EoU_3: Ease of positioning of head .318 .756
HYP_1: Bothered by others reactions to your red eyes .878
HYP_2: Self-conscious of eye redness .350 .825
HYP_3: Concern over cosmetic appearance of eyes .775
EFF_1: Prevention of future vision problems .761
EFF_2: Reduction of current visual problems .752
* Note: Factor loadings of less than .2 have been omitted. Factor I Eye Irritation 17.2% Factor II Convenience of Use 16.1% Factor III 
Ease of Use 15.3%Factor IV Hyperemia 15.2% Factor V Effectiveness 8.1%Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/67
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Individual scores were computed by equating the scale
range of items, adding the scale values of items within a
factor, and transforming the resulting value into a score
between 0 and 100. Higher scores were indicative of
greater satisfaction. Examination of the distributional
characteristics of the resulting scales (Table 4) revealed the
presence of the data skew that is a typical characteristic of
treatment satisfaction data. As noted elsewhere [29], the
magnitude of the ceiling effect and accompanying skew is
greatest among scales measuring less common negative
events, with 53% (n = 131) of respondents reporting that
they did not experience any hyperemia and 25% (n = 63)
reporting no form of eye irritation. Given the small
number of items in each scale, one would expect low
internal consistency estimates. However, the Chronbach's
Alphas for each of the TSS-IOP scales were quite high, an
indication of conceptual coherence between scale items.
The one-week test-retest reliability coefficients (intra-class
correlations, ICC) were also adequate for all but the EFF
scale, and ranged from .71 to .86. The EFF scale which
manifested some score instability over a one-week period
possessed an ICC of .41. Nevertheless, these values should
be interpreted with caution as larger samples are typically
required for adequate estimation of test-retest statistics.
Table 5 presents the Spearman Rho intercorrelations
between the five scales of the TSS-IOP. As might be
expected, the greatest conceptual overlap was observed
between EofU and CofU (r = .56). EI and HYP were also
correlated at .40. The correlation of EofU and CofU with
EFF was bit higher than expected (r = .40 and .43 respec-
tively) although low enough to suggest a degree of con-
ceptual distinctiveness of these measurement constructs.
Table 6 presents the item-to-scale correlations for each of
the five scales. Strong loadings of items on its respective
scale replicate observations of high internal consistency of
scale items and the factorial distinctiveness of scales. Sim-
ilar patterns of intercorrelations between items and unre-
lated TSS-IOP scales reveals a moderate association
between CofU and EofU, also observed in the inter-scale
correlation table presented above.
Convergent Validity
Scales of the TSQM, a previously validated TS-M instru-
ment, were used to examine the convergent validity of the
new TSS-IOP scales. Conceptually related dimension on
the TSQM and TSS-IOP were expected to exhibit moderate
to large correlations (.5–.8) with one another. Table 7
reveals that this was indeed the case for the satisfaction
scores on EFF, CofU and EofU. The lower correlations
between the TSQM Side Effects scale and the TSS-IOP EI
and HYP scales may suggest that patients think about side
effect items on these two instruments somewhat differ-
ently. A final observation was that the pattern of correla-
tions of the TSQM Global scale with both the TSQM
specific scales and the TSQM-IOP specific scales was very
similar
Table 4: Score Distribution and Internal Consistency Characteristics of TSS-IOP Scales (n = 250)
TSS-IOP Scales Mean (SD) 
Statistic
Number of 
Items
Chronbach's 
Alpha
Skewness 
Statistic
% Ceiling Test-Retest 
Reliability 
(ICC's)
Hyperemia 91.3 (17.7) 3 .84 -2.89 65.3% .86
Eye Irritation 91.2 (14.3) 4 .80 -2.71 48.4% .71
Convenience of 
Use
80.2 (15.4) 3 .86 -.53 20.8% .78
Ease of Use 68.9 (21.0) 3 .86 -.58 10.8% .86
Effectiveness 77.0 (16.7) 2 .83 -.95 14.9% .41
Table 5: Inter-scale Spearman Rho Correlations on the TSS-IOP
Effectiveness Eye Irritation Hyperemia Convenience of Use
Eye Irritation .19***
Hyperemia .27*** .40***
Convenience of Use .43*** .21*** .30***
Ease of Use .40*** .24*** .22*** .56***
* p < .05 level (2-tailed) ** p < .01 level (2-tailed). *** p < .001 (2-tailed)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/67
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Table 6: TSS-IOP Item-Scale Spearman Rho Correlations
TSS-IOP Items Effectiveness Eye Irritation Hyperemia Convenience of Use Ease of Use
EFF_1 .92 .18 .21 .40 .40
EFF_2 .95 .18 .26 .34 .40
EI_1 .17 .63 .34 .17 .22
EI_2 .16 .68 .26 .14 .11
EI_3 .16 .70 .39 .18 .17
EI_4 .12 .68 .32 .23 .18
Hyp_1 .23 .38 .88 .15 .26
Hyp_2 .20 .23 .71 .10 .17
Hyp_3 .21 .28 .72 .24 .30
EofU_1 .33 .22 .20 .89 .51
EofU _2 .36 .15 .18 .88 .45
EofU _3 .32 .28 .22 .86 .52
CofU_1 .49 .18 .23 .49 .89
CofU_2 .40 .17 .26 .49 .92
CofU_3 .30 .21 .28 .50 .86
* All correlation is significant at the .05 level (2-tailed).
Table 7: Convergence of the TSS-IOP Scales and the TSQM (Spearman Rho Correlations)
TSQM GLOBAL TSQM Effectiveness TSQM Side Effects TSQM Convenience
TSQM Scales
Effectiveness .52***
Side Effects .29*** .31***
Convenience .40*** .30*** .36***
TSS-IOP Scales
Effectiveness .50*** .77*** .34*** .34***
Eye Irritation .20** .18** .45*** .32***
Hyperemia .21*** .19** .36*** .34***
Convenience of Use .48*** .40*** .35*** .68***
Ease of Use .41*** .36*** .28*** .62***
* p < .05 level (2-tailed) ** p < .01 level (2-tailed). *** p < .001 (2-tailed)
Table 8: Respondents' Dissatisfaction Ratings Correlated with Specific Problematic Treatment Effects (Spearman Rho Correlations)
TSS-IOP TSQM
Frequency of... Hyperemia (Level 3) Eye Irritation (Level 3) Side Effects (Level 2) GLOBAL (Level 1)
Itching -.24*** -.35*** -.35*** .08
Burning -.28*** -.37*** -.25*** .15*
Stinging -.36*** -.41*** -.31*** .14*
Grittiness -.26*** -.56*** -.32*** .08
Tearing -.21*** -.32*** -.20** .14*
Dryness -.31*** -.54*** -.26*** .14*
Puffiness-Swelling -.35*** -.41*** -.24*** .14*
Red Eyes -.52*** -.41*** -.35*** .20***
Twitching-Tight Lids -.20*** -.31*** -.24*** .10
Degree of...
Eye Lash Growth -.12* -.21*** -.14* .01
Baggy Eye Lids -.41*** -.32*** -.29*** .15*
Iris Pigmentation -.24*** -.23*** -.16** .01
Darkened Eye Lids -.29*** -.25*** -.26*** .12
* p < .05 level (2-tailed) ** p < .01 level (2-tailed). *** p < .001 (2-tailed)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/67
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Criterion-Related Validity: Subgroup Comparisons
The expected correlations were found between patients'
frequency ratings of specific problems associated with
treatment and their ratings of satisfaction with the side
effects of treatment. These associations between the fre-
quency endorsement of undesirable events and satisfac-
tion levels were observed using both instruments (i.e.,
TSQM Global and Side Effects scales and the TSS-IOP IE
and HYP scales), with stronger correlational associations
found on Level 3 scales than the more general Level 2 or
Level 1 scales. Interestingly, clinical ratings of the severity
of unintended medication effects were significantly corre-
lated with relatively few of the patients' frequency ratings,
the notable exceptions were, red eyes (r = .21, p < .001),
twitching/tight eye lids (r = .16, p < .05), iris pigmentation
(r = .14, p < .05) and darkening of the eye lids (r = .17, p
< .01).
In a similar manner, patients' reported problems with self-
administration of their medication were weakly correlated
with relatively few of physicians' ratings of these problems
(problems of self-administration, r = .15, p < .05; antici-
patory blinks, r = .15, p < .05; and medication spillage, r =
.12, p < .05). In contrast, the correlations between
patients' difficulty ratings of medication administration
and their satisfaction on the TSQM Convenience scale and
the CofU and EofU TSS-IOP scales were stronger (Table
9). Inspection of Level 3 TSS-IOP ratings revealed an expe-
riential distinction between EoU and CoU by the type of
self-administration problem, these distinctions were not
discernable at more general levels of abstraction (Levels 2
and 1). Again, the correlations between specific experi-
ences and more general Levels 1 and 2 TSQM satisfaction
ratings were weaker than on the Level 3 scales of the TSS-
IOP.
Table 9: Convenience Satisfaction Ratings Correlated with Frequency of Specific Difficulties with Administration (Spearman Rho 
Correlations)
TSS-IOP Ease of Use 
(Level 3)
TSS-IOP Convenience 
of Use (Level 3)
TSQM Convenience 
(Level 2)
TSQM GLOBAL 
(Level 1)
Problems self-administering -.52*** -.30*** -.42*** -.28***
Requiring assistance -.23*** -.02 -.17** -.06
Frequency missing eye -.44*** -.29*** -.33*** -.09
Anticipatory blink and 
spillage
-.30*** -.23*** -.30*** -.15*
Trouble positioning head -.43*** -.34*** -.34*** -.19**
Delivering too much 
medication
-.45*** -.29*** -.27*** -.16**
Forgetting to use 
medication
-.17** -.38*** -.26*** -.11
* p < .05 level (2-tailed) ** p < .01 level (2-tailed). *** p < .001 (2-tailed)
Table 10: Convergent Validation of Patients' Satisfaction Ratings Using Physicians' Ratings of Patient Case (Spearman Rho 
Correlations)
PHYSICIANS' RATINGS
Degree of IOP Control Severity of Side Effects Compliance w/ 
Medication Regimen
Problems w/ Self-
Administration
TSQM Scales
GLOBAL .18** -.13* .00 -.12
Effectiveness .26*** -.14* .00 -.06
Side Effects .16* -.35*** .04 -.17**
Convenience .06 -.03 .04 -.23***
TSS-IOP Scales
Effectiveness .26*** -.16* .03 -.09
Eye Irritation .08 -.22*** .10 -.11
Hyperemia .11 -.18** .01 -.16*
Convenience of Use .18** -.05 .06 -.16*
Ease of Use .07 -.08 .04 -.13*
* p < .05 level (2-tailed) ** p < .01 level (2-tailed). *** p < .001 (2-tailed)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/67
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The correlations between patients' satisfaction ratings and
physicians' ratings of their patients on the core treatment
dimensions of IOP control, severity of side effects,
compliance, and difficulties with self-administration (see
Table 10) provided evidence for the concurrent clinical
criterion-related validity of the TSQM and TSS-IOP scales.
Stronger associations were observed between physicians'
ratings and the most conceptually related treatment satis-
faction scales. Interestingly, doctors' ratings of the severity
of side effects and problems with self-administration of
medication were more highly correlated with patients' sat-
isfaction in these areas than they were with the frequency
or degree of any actual events. A final observation was that
physicians' ratings of compliance were not significantly
correlated with any dimension of patients' satisfaction
ratings.
With the exception of HYP and EI, patients' self-reported
level of resistance to using their medication was negatively
correlated with all aspects of their satisfaction with treat-
ment. The same was found for another subjective or emo-
tionally based measure, patients' ratings of their
acceptance of their illness (Table 11). Of note, these emo-
tionally based appraisals of illness acceptance and treat-
ment resistance most correlated with the Level 1 global
scale scores. Patients' ratings of their tendency to forget to
use their medication were most strongly correlated with
the TSQM Convenience scale and particularly the CofU
scale of the TSS-IOP.
Evidence of Known Groups Validity: Satisfaction by 
Medications Groups
A comparison of persons on single (60%, n = 151) versus
multiple topical medications (40%, n = 99) by the dimen-
sions of treatment satisfaction revealed that the
monotherapeutic group was more satisfied than the poly-
therapeutic group on the TSQM Side Effects scale (93.4
(12.7) vs. 88.7 (15.2), F(1, 243) = 6.67, p = .01), and the
TSS-IOP EI scale (93.4 (11.1) vs. 87.5 (17.8), F(1, 243) =
10.4, p = .001), CofU scale (82.5 (14.2) vs. 77.1 (16.8),
F(1, 243) = 7.47, p = .007) and the EFF scale (79.1 (15.4)
vs. 73.7 (18.0), F(1, 243) = 6.19, p = .014). Monothera-
peutic respondents on Beta Blockers (n = 34) and Pros-
tagladins (n = 80) reported the highest satisfaction levels
with CofU, followed by those on Carbonic Anhydrase (n
= 22) and Alpha Agonists (n = 12), (85.3 (14.5), 83.6
(14.0), 79.3 (14.3) and 73.6 (11.1) respectively, F(3,144)
= 2.62, p = .05). Respondents on Beta Blockers also
reported the highest satisfaction with HYP, followed by
Carbonic Anhydrase Inhibitors, Prostagladins and Alpha
Agonists (99.3 (3.2), 93.6 (8.1), 90.7 (17.8) and 88.2
(27.2) respectively, F(3,144) = 2.79, p = .04).
Of those on monotherapy, 11% (n = 16) reported admin-
istering their medications in the morning, 46% (n = 69)
in the evening and 41% (n = 62) administered them in
both the morning and evening. A comparison of respond-
ents based on the time of day of medication
administration affirmed focus group discussion and
revealed that among monotherapeutic patients, the low-
est CofU ratings occurred for those using medications
both morning and evening, followed by evening adminis-
tration, with the highest satisfaction among morning
users (77.6 (SD15.9), 83.8 (13.4), 89.6 (12.5), F(3) =
7.31, p = .001).
Discussion
This initial psychometric analysis of the TSS-IOP revealed
the instrument possesses a sound conceptual structure
(construct validity), all but one TSS-IOP scale possessed
reliable assessment characteristics, and, on most dimen-
sions the scales manifested the expected convergent valid-
Table 11: Acceptance of Illness and Resistance to Using Medication by Satisfaction Levels (Spearman Rho Correlations)
Acceptance of Illness Resistance to Using 
Medication
Forgetting to Take 
Medication
TSQM Scales
GLOBAL .38*** -.32*** -.12
Effectiveness .29*** -.28*** -.18*
Side Effects .26*** -.18** -.20*
Convenience .19** -.16* -.28**
TSS-IOP Scales
Effectiveness .27*** -.29*** -.26**
Eye Irritation .08 -.07 -.05
Hyperemia .05 -.09 -.12
Convenience .27*** -.24*** -.39***
Ease of Use .22*** -.15* -.19*
* p < .05 level (2-tailed) ** p < .01 level (2-tailed). *** p < .001 (2-tailed)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/67
Page 11 of 13
(page number not for citation purposes)
ity using an established measure of TS-M. Some construct
divergence was observed from the TSQM Side Effects con-
struct, which was manifested by lower than expected cor-
relations between the HYP and EI scales of the TSS-IOP
and Side Effects scale of the TSQM. A supplemental anal-
ysis of TSS-IOP EI and HYP scales with TSQM Side Effect
items revealed low item to scale correlations on TSQM
items pertaining to the impact of side effects on the men-
tal and physical health of patients. Neither the physical
and mental impacts of OH/POAG treatments were
emphasized as important aspects of topical OH treat-
ments by a significant number of focus group participants
and thus were not covered by content of the TSS-IOP side
effect scales.
Of note, there was significant debate among researchers
over the meaningfulness of including the two EFF items in
the TSS-IOP since it is believed that patients cannot relia-
bly detect or report on treatment-related changes in vision
associated with reduction in intraocular pressure. It was
eventually decided that these items should be included
because a significant number of focus group members,
particularly those in the earlier stages of disease, empha-
sized the importance of changes in their visual acuity as a
result of treatment. Since the clinical meaningfulness of
patient reported changes in visual problems associated
with OH treatments has yet to be established or refuted,
inclusion of the EFF scale can, at the very least, be consid-
ered an attempt to retain the face validity of the TSS-IOP
to patients – who recognize this as the most important
reason for taking their medication in the first place. The
poor test-retest stability of the EFF scale may reflect
patients' inability to reliably discern and report on this
dimension of IOP treatment. Alternatively, such 'instabil-
ity' may reflect real fluctuation or changes in clinical
measurement of IOP. Supporting this possibility, a
significant correlation was observed between patients' EFF
satisfaction scores and clinician's ratings of IOP control,
suggesting that patients derive at least some of the infor-
mation with which to make satisfaction judgments
directly from results reported during the clinical assess-
ment process. Notably, a significant number of focus
group members knew their IOP levels as communicated
by their physicians at visits.
The concurrent criterion-related validity of the TSS-IOP
two side effect scales and two convenience scales were
demonstrated by a clear association with a fundamental
set of criterion measures, namely patients' ratings of the
frequency and severity of various problems associated
with their use of the medication. These criterion-related
validity results suggest that patients' satisfaction ratings on
the IE and HYP scales were differentially based on some-
what distinct aspects of patient experience, as were the
two convenience scales. In addition, the TSS-IOP provides
further conceptual distinction to the TSQM Convenience
construct, in that the new instrumentation successfully
discriminates between patients' satisfaction with a treat-
ment scheduling from satisfaction with the ease of use of
delivery technology. Evidence for the 'known groups'
validity of the EI, HYP, CofU and EofU scales was found
since TSS-IOP scores on these scales differed significantly
between classes of medication as well as by the frequency
of daily medication administration. These differences
were consistent with differences in patient satisfaction
that are known to occur within clinical practice.
Compared to the Level 1 scale of the TSQM, the higher
correlations of the TSS-IOP (Level 3) scales and patients'
reports of specific treatment difficulties support the
commonly assumed measurement benefits of using more
specific TS-M scales as an means for the differentiation of
pharmaceutical products; in this case, the dimensions of
EI, HYP, CoU, and EoU associated with topical ophthal-
mic medications. The greater event/situational specificity
of Level 3 scales allows for more focused statements to be
made about the associations between problematic effects
of treatment and patients' dissatisfaction.
Despite earlier concerns raised about the content validity
of the side effects and convenience scales of the TSQM in
this population, certain advantages were found to using
these more generally worded items and scales of the
TSQM. The Level 2 and Level 1 scales of the TSQM seemed
to possess greater explanatory power with respect to clini-
cians' ratings of treatment side effects and difficulties their
patients had with medication use. In addition, Level 1
and, to some degree, Level 2 TSQM scales were more
strongly correlated with patients' ratings of their own
resistance to regular medication use than the Level 3 scales
of the TSS-IOP. There is a need for future clinical research
to assess the degree to which dimensions and levels of TS-
M assessment are able to predict actual medication-related
behaviors such as compliance and persistence with medi-
cation regimens, as well as a need to more clearly specify
how non-compliance affects broader health outcomes
among persons with POAG. Such associations could have
important ramifications for numerous stakeholders
involved in health care delivery, including those in the
pharmaceutical industry, regulatory agencies, health man-
agement organizations, and professionals providing clin-
ical care.
A final observation was the scarcity of significant correla-
tions between patients' frequency ratings of undesirable
treatment experiences and clinicians' ratings of problems
with side effects of medication use. This might suggest
that the involved practitioners use relatively few specific
indicators to assess these dimensions of treatment impact.
Also contributing to the low correlations, specific treat-Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/67
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ment-related events often vary across individuals, thereby
reducing the correlations observed between measures of
specific events and practitioners' general clinical assess-
ments across a heterogeneous sample of patients. Interest-
ingly, patients' satisfaction ratings were more highly
correlated with physicians' ratings of side effect than with
patients' frequency ratings of undesirable aspects of treat-
ment. This raises the possibility that patients' expression
of satisfaction or dissatisfaction in the clinical setting may
influence physicians' clinical impression on certain clini-
cal assessment dimensions, this in turn suggests that treat-
ment satisfaction could play a role in clinical decisions in
regards to prescribing, adjusting, and/or switching medi-
cation regimens. Further research is required to examine
the clinical usefulness of treatment satisfaction
assessments and their role in the clinical decision-making
process.
Conclusions
Results from this initial validation study of the TSS-IOP
indicate that the measure is psychometrically sound and
provides a means to assess important aspects of patients'
experiences with the two dimensions of side effects and
two dimensions of convenience associated with topical
eye medications used in the control of OH. Results from
the two side effect scales (Hyperemia and Eye Irritation)
demonstrate their ability to differentiate between medica-
tions clinically known to differ on these dimensions.
Results from the Effectiveness scale suggest that this scale
reflects patient reported perception of effectiveness, likely
a result of professional opinion about a medication's abil-
ity to manage OH.
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